Advertisement

Preoperative Evaluation and Care of Heart Transplant Candidates

      Heart transplantation is recommended for patients with advanced heart failure refractory to medical and device therapy, and who do not have absolute contraindications. When patients become eligible for heart transplantation, they undergo comprehensive evaluation and preparation to optimize their posttransplantation outcomes. This review provides an overview of the processes that are employed to enable the candidates to be transplant-ready when donor hearts are available.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiothoracic and Vascular Anesthesia
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • McDonagh TA
        • Metra M
        • Adamo M
        • et al.
        2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
        Eur Heart J. 2021; 42: 3599-3726
        • Wilhelm MJ.
        Long-term outcome following heart transplantation: Current perspective.
        J Thorac Dis. 2015; 7: 549-551
        • Alraies MC
        • Eckman P.
        Adult heart transplant: Indications and outcomes.
        J Thorac Dis. 2014; 6: 1120-1128
        • Khush KK
        • Cherikh WS
        • Chambers DC
        • et al.
        The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty sixth adult heart transplantation report — 2019; focus theme: Donor and recipient size match.
        J Heart Lung Transplant. 2019; 38: 1056-1066
        • Khush KK
        • Cherikh WS
        • Chambers DC
        • et al.
        The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation (ISHLT): Thirty-fifth Adult Heart and Lung Transplantation Report — 2018; focus theme: Multiorgan transplantation.
        J Heart Lung Transplant. 2018; 30: 1155-1168
        • Estep JD
        • Soltesz E
        • Cogswell R.
        The new heart transplant allocation system: Early observations and mechanical circulatory support considerations.
        J Thorac Cardiovasc Surg. 2020; 161: 1839-1846
        • Wever-Pinzon O
        • Edwards LB
        • Taylor DO
        • et al.
        Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management-an analysis of the International Society for Heart and Lung Transplantation Registry.
        J Heart Lung Transplant. 2017; 36: 407-417
        • Nilsson J
        • Ansari D
        • Ohlsson M
        • et al.
        Human leukocyte antigen-based risk stratification in heart transplant recipients - implications for targeted surveillance.
        J Am Heart Assoc. 2019; 8e011124
        • Nakamura T
        • Shirouzu T
        • Nakata K
        • et al.
        The role of major histocompatibility complex in organ transplantation- donor specific anti-major histocompatibility complex antibodies analysis goes to the next stage.
        Int J Mol Sci. 2019; 20: 4544
        • Wright M
        • Takeda K
        • Mauro C
        • et al.
        Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation.
        J Heart Lung Transplant. 2017; 36: 1226-1233
        • Cooper LB
        • Mentz RJ
        • Edwards LB
        • et al.
        Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality.
        J Heart Lung Transplant. 2017; 36: 202-210
        • Lund LH
        • Edwards LB
        • Kucheryavaya AY
        • et al.
        The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report–2015; focus theme: Early Graft Failure.
        J Heart Lung Transplant. 2015; 34: 1244-1254
        • De Rosa N
        • Paddon VL
        • Liu Z
        • et al.
        Nonmelanoma Skin Cancer Frequency and Risk Factors in Australian Heart and Lung Transplant Recipients.
        JAMA Dermatol. 2019; 155: 716-719
        • Mudigonda T
        • Levender MM
        • O'Neill JL
        • et al.
        Incidence, risk factors, and preventative management of skin cancers in organ transplant recipients: A review of single- and multicenter retrospective studies from 2006 to 2010.
        Dermatol Surg. 2013; 39: 345-364
        • Gogia R
        • Binstock M
        • Hirose R
        • et al.
        Fitzpatrick skin phototype is an independent predictor of squamous cell carcinoma risk after solid organ transplantation.
        J Am Acad Dermatol. 2013; 68: 585-591
        • Khush KK
        • Hsich E
        • Potena L
        • et al.
        The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report - 2021; focus on recipient characteristics.
        J Heart Lung Transplant. 2021; 40: 1035-1049
        • Mehra MR
        • Canter CE
        • Hannan MM
        • et al.
        The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update.
        J Heart Lung Transplant. 2016; 35: 1-23
        • Costanzo MR
        • Dipchand A
        • Starling R
        • et al.
        The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients.
        J Heart Lung Transplant. 2010; 29: 914-956
        • Kaczmarek I
        • Deutsch MA
        • Kauke T
        • et al.
        Donor-specific HLA alloantibodies: Long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.
        Exp Clin Transplant. 2008; 6: 229-235
        • Klein J
        • Sato A.
        The HLA system: First of two parts.
        N Engl J Med. 2000; 343: 702-709
        • Klein J
        • Sato A.
        The HLA system. Second of two parts.
        N Engl J Med. 2000; 343: 782-786
        • Terasaki PI
        • McClelland JD.
        Microdroplet assay of human serum cytotoxins.
        Nature. 1964; 204: 998-1000
        • Colvin MM
        • Cook JL
        • Chang PP
        • et al.
        Sensitization in heart transplantation: Emerging knowledge: A scientific statement from the American Heart Association.
        Circulation. 2019; 139: e553-e578
        • Bray RB
        • Harris SB
        • Josephson CD
        • et al.
        Unappreciated risk factors for transplant patients: HLA antibodies in blood components.
        Hum Immunol. 2004; 65: 240-244
        • Welters MJ
        • Oei FB
        • Witvliet MD
        • et al.
        A broad and strong humoral immune response to donor HLA after implantation of cryopreserved human heart valve allografts.
        Hum Immunol. 2002; 63: 1019-1025
        • Lietz K
        • John R
        • Kocher A
        • et al.
        Increased prevalence of autoimmune phenomena and greater risk for alloreactivity in female heart transplant recipients.
        Circulation. 2001; 104 (I-177-83)
        • Eckman PM
        • Hanna M
        • Taylor DO
        • et al.
        Management of the sensitized adult heart transplant candidate.
        Clin Transplant. 2010; 24: 726-734
        • Urban M
        • Gazdic T
        • Slimackova E
        • et al.
        Alloimmunosensitization in left ventricular assist device recipients and impact on post transplantation outcome.
        ASAIO J. 2012; 58: 554-561
        • Dvorak L
        • Pirk J
        • Cerny S
        • et al.
        The role of leukocyte depleting filters in heart transplantation: Early outcomes in prospective, randomized clinical trial.
        Eur J Cardiothorac Surg. 2006; 30: 621-627
        • Ponikowski P
        • Voors AA
        • Anker SD
        • et al.
        2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
        Eur J Heart Fail. 2016; 18: 891-975
        • Moazami N
        • Itescu S
        • Williams MR
        • et al.
        Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support.
        J Heart Lung Transplant. 1998; 17: 876-880
        • Newell H
        • Smith JD
        • Rogers P
        • et al.
        Sensitization following LVAD implantation using leucodepleted blood is not due to HLA antibodies.
        Am J Transplant. 2006; 6: 1712-1717
        • Drakos SG
        • Stringham JC
        • Long JW
        • et al.
        Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: The impact of leukofiltered cellular blood product transfusions.
        J Thorac Cardiovasc Surg. 2007; 133: 1612-1619
        • Netuka I
        • Kvasnicka T
        • Kvasnicka J
        • et al.
        Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure.
        J Heart Lung Transplant. 2016; 35: 860-867
        • Bansal A
        • Uriel N
        • Colombo PC
        • et al.
        Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial.
        J Heart Lung Transplant. 2019; 38: 806-816
        • Netuka I
        • Ivak P
        • Tučanová Z
        • et al.
        Evaluation of low-intensity anticoagulation with a fully magnetically levitated centrifugal-flow circulatory pump-the MAGENTUM 1 study.
        J Heart Lung Transplant. 2018; 37: 579-586
        • George I
        • Colley P
        • Russo MJ
        • et al.
        Association of device surface and biomaterials with immunologic sensitization after mechanical support.
        J Thorac Cardiovasc Surg. 2008; 135: 1372-1379
        • Itescu S
        • John R.
        Interactions between the recipient immune system and the left ventricular assist device surface: Immunological and clinical implications.
        Ann Thorac Surg. 2003; 75: S58-S65
        • Schuster M
        • Kocher A
        • John R
        • et al.
        B-cell activation and allosensitization after left ventricular assist device implantation is due to T-cell activation and CD40 ligand expression.
        Hum Immunol. 2002; 63: 211-220
        • Pagani FD
        • Dyke DB
        • Wright S
        • et al.
        Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival.
        J Heart Lung Transplant. 2001; 20: 646-653
        • Askar M
        • Hsich E
        • Reville P
        • et al.
        HLA and MICA allosensitization patterns among patients supported by ventricular assist devices.
        J Heart Lung Transplant. 2013; 32: 1241-1248
        • Kwon MH
        • Zhang JQ
        • Schaenman JM
        • et al.
        Characterization of ventricular assist device-mediated sensitization in the bridge-to-heart transplantation patient.
        J Thorac Cardiovasc Surg. 2015; 149: 1161-1166
        • See SB
        • Clerkin KJ
        • Kennel PJ
        • et al.
        Ventricular assist device elicits serum natural IgG that correlates with the development of primary graft dysfunction following heart transplantation.
        J Heart Lung Transplant. 2017; 36: 862-870
        • Bourque K
        • Cotter C
        • Dague C
        • et al.
        Design rationale and preclinical evaluation of the HeartMate 3 left ventricular assist system for hemocompatibility.
        ASAIO J. 2016; 62: 375-383
        • Kobashigawa JA
        • Patel JK
        • Kittleson MM
        • et al.
        The long-term outcome of treated sensitized patients who undergo heart transplantation.
        Clin Transplant. 2011; 25: E61-E67
        • Lund LH
        • Khush KK
        • Cherikh WS
        • et al.
        The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report-2017; Focus Theme: Allograft ischemic time.
        J Heart Lung Transplant. 2017; 36: 1037-1046
        • Ho EK
        • Vlad G
        • Colovai AI
        • et al.
        Alloantibodies in heart transplantation.
        Hum Immunol. 2009; 70: 825-829
        • Nwakanma LU
        • Williams JA
        • Weiss ES
        • et al.
        Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era.
        Ann Thorac Surg. 2007; 84: 1556-1562
        • Opelz G
        • Wujciak T.
        The influence of HLA compatibility on graft survival after heart transplantation.
        N Engl J Med. 1994; 330: 816-819
        • Kobashigawa J
        • Colvin M
        • Potena L
        • et al.
        The management of antibodies in heart transplantation: An ISHLT consensus document.
        J Heart Lung Transplant. 2018; 37: 537-547
        • Ratkovec RM
        • Hammond E H
        • O'Connell J B
        • et al.
        Outcome of cardiac transplant recipients with a positive donor-specific crossmatch–preliminary results with plasmapheresis.
        Transplantation. 1992; 54: 651-655
        • Singh N
        • Pirsch J
        • Samaniego M.
        Antibody-mediated rejection: Treatment alternatives and outcomes.
        Transplant Rev. 2009; 23: 34-46
        • Ballow M.
        The IgG molecule as a biological immune response modifier: Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders.
        J Allergy Clin Immunol. 2011; 127: 315-323
        • John R
        • Lietz K
        • Burke E
        • et al.
        Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients.
        Circulation. 1999; 100: II229-II235
        • Gelfand EW.
        Antibody-directed therapy: Past, present, and future.
        J Allergy Clin Immunol. 2001; 108: S111-S116
        • Dwyer JM.
        Manipulating the immune system with immune globulin.
        N Engl J Med. 1992; 326: 107-116
        • Everly JJ
        • Walsh RC
        • Alloway RR
        • et al.
        Proteasome inhibition for antibody-mediated rejection.
        Curr Opin Organ Transplant. 2009; 14: 662-666
        • Patel J
        • Everly M
        • Chang D
        • et al.
        Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
        J Heart Lung Transplant. 2011; 30: 1320-1326
        • Rhen T
        • Cidlowski JA.
        Antiinflammatory action of glucocorticoids - new mechanisms for old drugs.
        N Engl J Med. 2005; 353: 1711-1723
        • Lick SD
        • Vaidya S
        • Kollar AC
        • et al.
        Peri-operative alemtuzumab (Campath-1H) and plasmapheresis for high-PRA positive lymphocyte crossmatch heart transplant: A strategy to shorten left ventricular assist device support.
        J Heart Lung Transplant. 2008; 27: 1036-1039
        • Patel J
        • Dilibero D
        • Kittleson M
        • et al.
        Terminal complement inhibition for highly sensitized patients undergoing heart transplantation: Doable?.
        J Heart Lung Transplant. 2015; 34 (2015): S31
        • Colvin MM
        • Cook JL
        • Chang P
        • et al.
        Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: A scientific statement from the American Heart Association.
        Circulation. 2015; 131: 1608-1639
        • Kobashigawa J
        • Mehra M
        • West L
        • et al.
        Report from a consensus conference on the sensitized patient awaiting heart transplantation.
        J Heart Lung Transplant. 2009; 28: 213-225
        • Doumouras BS
        • Fan CPS
        • Mueller B
        • et al.
        The effect of pre–heart transplant body mass index on posttransplant outcomes: An analysis of the ISHLT Registry Data.
        Clin Transplant. 2019; 33: e13621
        • Ch Yap
        • M Mohajeri
        • Yii M
        Obesity and early complications after cardiac surgery.
        Med J Aust. 2007; 186: 350-354
        • Rehman SM
        • Elzain O
        • et al.
        Risk factors for mediastinitis following cardiac surgery: The importance of managing obesity.
        J Hosp Infect. 2014; 88: 96-102
        • Ranucci M
        • Ballota A
        • La Rovere MT
        • et al.
        Post-operative hypoxia and length of intensive care unit stay after cardiac surgery: The underweight paradox?.
        PLoS One. 2014; 9: e93992
        • Phoon PHY
        • Hwang NC.
        Deep sternal wound infection: Diagnosis, treatment and prevention.
        J Cardiothorac Vasc Anesth. 2020; 34: 1602-1613
        • Hameed S
        • Salem V
        • Alessimii H
        • et al.
        Imperial satiety protocol: A new non-surgical weight-loss programme, delivered in a health care setting, produces improved clinical outcomes for people with obesity.
        Diabetes Obes Metab. 2021; 23: 270-275
        • Evangelista LS
        • Jose MM
        • Sallam H
        • et al.
        High-protein vs. standard-protein diets in overweight and obese patients with heart failure and diabetes mellitus: Findings of the Pro-HEART trial.
        ESC Heart Fail. 2021; 8: 1342-1348
        • Poirier P
        • Cornier MA
        • Mazzone T
        • et al.
        Bariatric surgery and cardiovascular risk factors: Aa scientific statement from the American Heart Association.
        Circulation. 2011; 123: 1683-1701
        • Caceres M
        • Czer LSC
        • Esmailian F
        • et al.
        Bariatric surgery in severe obesity and end-stage heart failure with mechanical circulatory support as a bridge to successful heart transplantation: A case report.
        Transplant Proc. 2013; 45: 798-799
        • daSilva-deAbreu A
        • Alhafez BA
        • Curbelo-Pena Y
        • et al.
        Bariatric surgery in patients with obesity and ventricular assist devices considered for heart transplantation: Systematic review and individual participant data meta-analysis.
        J Card Fail. 2021; 27: 338-348
        • Lim CP
        • Fisher OM
        • Falkenback D
        • et al.
        Bariatric surgery provides a "bridge to transplant" for morbidly obese patients with advanced heart failure and may obviate the need for transplantation.
        Obes Surg. 2016; 26: 486-493
        • Russo MJ
        • Hong KN
        • Davies RR
        • et al.
        The effect of body mass index on survival following heart transplantation: Do outcomes support consensus guidelines?.
        Ann Surg. 2010; 251: 144-152
        • Karkouti K
        • Grocott HP
        • Hall R
        • et al.
        Interrelationship of preoperative anemia, intraoperative anemia, and red blood cell transfusion as potentially modifiable risk factors for acute kidney injury in cardiac surgery: A historical multicentre cohort study.
        Can J Anaesth. 2015; 62: 377-384
        • Chew STH
        • Hwang NC.
        Acute kidney injury after cardiac surgery: A narrative review of the literature.
        J Cardiothorac Vasc Anesth. 2019; 33: 1122-1138
        • Carr JG
        • Stevenson LW
        • Walden JA
        • et al.
        Prevalence and hemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
        Am J Cardiol. 1989; 63: 709-713
        • Anker SD
        • Chua TP
        • Ponikowski P
        • et al.
        Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia.
        Circulation. 1997; 96: 526-534
        • Kalantar-Zadeh S
        • Anker T
        • Horwich G
        • et al.
        Nutritional and anti-inflammatory interventions in chronic heart failure.
        Am J Cardiol. 2008; 101 (89E–103)
        • Jha SR
        • Hannu MK
        • Chang SW
        • et al.
        The prevalence and prognostic significance of frailty in patients with advanced heart failure referred for heart transplantation.
        Transplantation. 2016; 100: 429-436
        • Bottiger BA
        • Nicoara A
        • Snyder LD
        • et al.
        Frailty in the end-stage lung disease or heart failure patient: Implications for the perioperative transplant clinician.
        J Cardiothorac Vasc Anesth. 2018; 33: 1382-1392
        • Lund LH
        • Edwards LB
        • Dipchand AI
        • et al.
        The Registry of the International Society for Heart and Lung Transplantation: Thirty-third adult heart transplantation report—2016; focus theme: Primary diagnostic indications for transplant.
        J Heart Lung Transplant. 2016; 35: 1158-1169
        • Chen YW
        • Wang CY
        • Lai YH
        • et al.
        Home-based cardiac rehabilitation improves quality of life, aerobic capacity, and readmission rates in patients with chronic heart failure.
        Medicine (Baltimore). 2018; 97: e9629
        • Sabbag A
        • Mazin I
        • Rott D
        • et al.
        The prognostic significance of improvement in exercise capacity in heart failure patients who participate in cardiac rehabilitation programme.
        Eur J Prev Cardiol. 2018; 25: 354-361
        • Acanfora D
        • Scicchitano P
        • Casucci G
        • et al.
        Exercise training effects on elderly and middle-age patients with chronic heart failure after acute decompensation: A randomized, controlled trial.
        Int J Cardiol. 2016; 225: 313-323
        • Vromen T
        • Kraal JJ
        • Kuiper J
        • et al.
        The influence of training characteristics on the effect of aerobic exercise training in patients with chronic heart failure: A meta-regression analysis.
        Int J Cardiol. 2016; 208: 120-127
        • Gimeno-Santos E
        • Coca-Martinez M
        • Arguis MJ
        • et al.
        Multimodal prehabilitation as a promising strategy for preventing physical deconditioning on the heart transplant waiting list.
        Eur J Prev Cardiol. 2020; 27: 2367-2370
        • Arguis MJ
        • Navarro-Ripoll N
        • Lopez-Hernandez A
        • et al.
        Multimodal prehabilitation: A promising strategy in patients listed for heart transplantation.
        J Cardiothorac Vasc Anesth. 2019; 33: S105-S139
        • Curotto Grasiosi J
        • Peressotti B
        • Machado RA
        • et al.
        Improvement in functional capacity after levothyroxine treatment in patients with chronic heart failure and subclinical hypothyroidism.
        Endocrinol Nutr. 2013; 60: 427-432
        • Loh KC.
        Amiodarone-induced thyroid disorders: A clinical review.
        Postgrad Med J. 2000; 76: 133-140
        • Lau GT
        • Tan HC
        • Kritharides L.
        Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation.
        Am J Cardiol. 2002; 90: 1405-1409
        • Konstam MA
        • Kiernan MS
        • Bernstein D
        • et al.
        Evaluation and management of right-sided heart failure: A scientific statement from the American Heart Association.
        Circulation. 2018; 137: e578-e622
        • Mullens W
        • Abrahams Z
        • Francis GS
        • et al.
        Importance of venous congestion for worsening of renal function in advanced decompensated heart failure.
        J Am Coll Cardiol. 2009; 53: 589-596
        • Verbrugge FH
        • Dupont M
        • Steels P
        • et al.
        Abdominal contributions to cardiorenal dysfunction in congestive heart failure.
        J Am Coll Cardiol. 2013; 62: 485-495
        • Rodriguez Ziccardi M
        • Pendela VS
        • et al.
        Cardiac Cirrhosis.
        StatPearls. StatPearls Publishing, Treasure Island, FL2022
        • Kubo SH
        • Walter BA
        • John DH
        • et al.
        Liver function abnormalities in chronic heart failure. Influence of systemic hemodynamics.
        Arch Intern Med. 1987; 147: 1227-1230
        • Allen LA
        • Felker GM
        • Pocock S
        • et al.
        CHARM Investigators. Liver function abnormalities and outcome in patients with chronic heart failure: Data from the Candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program.
        Eur J Heart Fail. 2009; 11: 170-177
        • Eisen HJ.
        The MELD scoring system and the prediction of outcomes in heart failure patients: What we have learned from the hepatologists.
        J Am Coll Cardiol. 2013; 61: 2262-2263
        • Deo SV
        • Daly RC
        • Altarabsheh SE
        • et al.
        Predictive value of the model for end-stage liver disease score in patients undergoing left ventricular assist device implantation.
        ASAIO J. 2013; 59: 57-62
        • Gelow JM
        • Desai AS
        • Hochberg CP
        • et al.
        Clinical predictors of hepatic fibrosis in chronic advanced heart failure.
        Circ Heart Fail. 2010; 3: 59-64
        • Rangaswami J
        • Bhalla V
        • Blair JEA
        • et al.
        Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association.
        Circulation. 2019; 139: e840-e878
        • Husain-Syed F
        • Gröne HJ
        • Assmus B
        • et al.
        Congestive nephropathy: A neglected entity? Proposal for diagnostic criteria and future perspectives.
        ESC Heart Fail. 2021; 8: 183-203
        • Schrier RW
        • Abraham WT.
        Hormones and hemodynamics in heart failure.
        N Engl J Med. 1999; 341: 577-585
        • Bonios MJ
        • Terrovitis JV
        • Kaldara E.
        The challenge of treating congestion in advanced heart failure.
        Expert Rev Cardiovasc Ther. 2011; 9: 1181-1191
        • Liu PP.
        Cardiorenal syndrome in heart failure: A cardiologist's perspective.
        Can J Cardiol. 2008; 24 (25B–259)
        • Boyle JM
        • Moualla S
        • Arrigain S
        • et al.
        Risks and outcomes of acute kidney injury requiring dialysis after cardiac transplantation.
        Am J Kidney Dis. 2006; 48: 787-796
        • Jankowska EA
        • von Haehling S
        • Anker SD
        • et al.
        Iron deficiency and heart failure: Diagnostic dilemmas and therapeutic perspectives.
        Eur Heart J. 2013; 34: 816-829
        • Cohen-Solal A
        • Leclercq C
        • Mebazaa A
        • et al.
        Diagnosis and treatment of iron deficiency in patients with heart failure: Expert position paper from French cardiologists.
        Arch Cardiovasc Dis. 2014; 107: 563-571
        • Tkaczyszyn M
        • Comin-Colet J
        • Voors AA
        • et al.
        Iron deficiency and red cell indices in patients with heart failure.
        Eur J Heart Fail. 2018; 20: 114-122
        • Klip IT
        • Comin-Colet J
        • Voors AA
        • et al.
        Iron deficiency in chronic heart failure: An international pooled analysis.
        Am Heart J. 2013; 165 (e3): 575-582
        • Nanas JN
        • Matsouka C
        • Karageorgopoulos D
        • et al.
        Etiology of anemia in patients with advanced heart failure.
        J Am Coll Cardiol. 2006; 48: 2485-2489
        • Okonko DO
        • Mandal AK
        • Missouris CG
        • et al.
        Disordered iron homeostasis in chronic heart failure: Prevalence, predictors, and relation to anemia, exercise capacity, and survival.
        J Am Coll Cardiol. 2011; 58: 1241-1251
        • Parikh A
        • Natarajan S
        • Lipsitz SR
        • et al.
        Iron deficiency in community-dwelling US adults with self-reported heart failure in the National Health and Nutrition Examination Survey III: Prevalence and associations with anemia and inflammation.
        Circ Heart Fail. 2011; 4: 599-606
        • Yeo TJ
        • Yeo PSD
        • Wong CCR
        • et al.
        Iron deficiency in a multi-ethnic Asian population with and without heart failure: Prevalence, clinical correlates, functional significance and prognosis.
        Eur J Heart Fail. 2014; 16: 1125-1132
        • von Haehling S
        • Gremmler U
        • Krumm M
        • et al.
        Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP Registry.
        Clin Res Cardiol. 2017; 106: 436-443
        • McDonagh T
        • Macdougall IC.
        Iron therapy for the treatment of iron deficiency in chronic heart failure: Intravenous or oral?.
        Eur J Heart Fail. 2015; 17: 248-262
        • Nemeth E
        • Ganz T.
        The role of hepcidin in iron metabolism.
        Acta Haematol. 2009; 122: 78-86
        • Beard JL.
        Iron biology in immune function, muscle metabolism and neuronal functioning.
        J Nutr. 2001; 131 (568S–580S)
        • Jankowska EA
        • Rozentryt P
        • Witkowska A
        • et al.
        Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure.
        J Card Fail. 2011; 17: 899-906
        • Enjuanes C
        • Bruguera J
        • Grau M
        • et al.
        Iron status in chronic heart failure: Impact on symptoms, functional class and submaximal exercise capacity.
        Rev Esp Cardiol (Engl Ed). 2016; 69: 247-255
        • Comin-Colet J
        • Enjuanes C
        • Gonzalez G
        • et al.
        Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status.
        Eur J Heart Fail. 2013; 15: 1164-1172
        • Enjuanes C
        • Klip IT
        • Bruguera J
        • et al.
        Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study.
        Int J Cardiol. 2014; 174: 268-275
        • Nunez J
        • Comin-Colet J
        • Minana G
        • et al.
        Iron deficiency and risk of early readmission following a hospitalization for acute heart failure.
        Eur J Heart Fail. 2016; 18: 798-802
        • Jankowska EA
        • Rozentryt P
        • Witkowska A
        • et al.
        Iron deficiency: An ominous sign in patients with systolic chronic heart failure.
        Eur Heart J. 2010; 31: 1872-1880
        • Okonko DO
        • Grzeslo A
        • Witkowski T
        • et al.
        Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency. FERRIC-HF: A randomized, controlled, observer-blinded trial.
        J Am Coll Cardiol. 2008; 51: 103-112
        • Anker SD
        • Comin Colet J
        • Filippatos G
        • et al.
        Ferric carboxymaltose in patients with heart failure and iron deficiency.
        N Engl J Med. 2009; 361: 2436-2448
        • Ponikowski P
        • van Veldhuisen DJ
        • Comin-Colet J
        • et al.
        Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency.
        Eur Heart J. 2015; 36: 657-668
        • Jankowska EA
        • Tkaczyszyn M
        • Suchocki T
        • et al.
        Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: A meta-analysis of randomized controlled trials.
        Eur J Heart Fail. 2016; 18: 786-795
        • van Veldhuisen DJ
        • Ponikowski P
        • van der Meer P
        • et al.
        Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency.
        Circulation. 2017; 136: 1374-1383
        • Anker SD
        • Kirwan BA
        • van Veldhuisen DJ
        • et al.
        Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: An individual patient data meta-analysis.
        Eur J Heart Fail. 2018; 20: 125-133
        • Graham FJ
        • Pellicori P
        • Ford I
        • et al.
        Intravenous iron for heart failure with evidence of iron deficiency: A meta-analysis of randomised trials.
        Clin Res Cardiol. 2021; 110: 1299-1307
        • Ponikowski P
        • Kirwan BA
        • Anker SD
        • et al.
        Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: A multicentre, double-blind, randomised, controlled trial.
        Lancet. 2020; 396: 1895-1904
        • Lewis GD
        • Malhotra R
        • Hernandez AF
        • et al.
        Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: The IRONOUT HF randomized clinical trial.
        JAMA. 2017; 317: 1958-1966
      1. Vifor Pharma Ltd. Ferinject (ferric carboxymaltose). Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/5910/smpc#gref. Accessed January 23, 2022.

      2. Ahmed T, Jain A. Heart transplantation. Available at: https://www.ncbi.nlm.nih.gov/books/NBK557571/. Accessed January 23, 2022.

        • Nayak A
        • Dong T
        • Ko YA
        • et al.
        Validating patient prioritization in the 2018 Revised United Network for Organ Sharing Heart Allocation System: A single-center experience.
        Clin Transplant. 2020; 34: e13816
      3. Organ Procurement & Transplantation Network. Criteria requirements in adult heart allocation policy. Available at: https://optn.transplant.hrsa.gov/media/2413/adult_heart_criteria.pdf. Accessed January 23, 2022.

        • Dorent R
        • Jasseron C
        • Audry B
        • et al.
        New French heart allocation system: Comparison with Eurotransplant and US allocation systems.
        Am J Transplant. 2020; 20: 1236-1243
      4. United Network for Organ Sharing. Talking about Transplantation. Questions and answers for transplant candidates about heart allocation for adult candidates. Available at: https://unos.org/wp-content/uploads/unos/UNOS-110_heart.pdf. Accessed January 23, 2022.

      5. Organ Procurement & Transplantation Network. Continuous distribution. Available at: https://optn.transplant.hrsa.gov/governance/key-initiatives/continuous-distribution/. Accessed January 23, 2022.

        • Jasseron C
        • Legeai C
        • Jacquelinet C
        • et al.
        Prediction of waitlist mortality in adult heart transplant candidates: The Candidate Risk Score.
        Transplantation. 2017; 101: 2175-2182
      6. National Health Service. POL228/12 – Heart transplantation: Organ allocation. Available at: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/24240/pol228-12.pdf. Accessed January 23, 2022.

        • Kransdorf EP
        • Kittleson MM
        • Benck LR
        • et al.
        Predicted heart mass is the optimal metric for size match in heart transplantation.
        J Heart Lung Transplant. 2019; 38: 156-165
        • Cheshire C
        • Kydd A
        • Nerlekar N
        • et al.
        Size matching in heart transplantation: Is predicted heart mass the optimal method in a United Kingdom cohort?.
        Clin Transplant. 2014; 35: e14192
        • Bluemke DA
        • Kronmal RA
        • Lima JA
        • et al.
        The relationship of left ventricular mass and geometry to incident cardiovascular events: The MESA (Multi-Ethnic Study of Atherosclerosis) study.
        J Am Coll Cardiol. 2008; 52: 2148-2155
        • Kawut SM
        • Lima JA
        • Barr RG
        • et al.
        Sex and race differences in right ventricular structure and function: The multi-ethnic study of atherosclerosis-right ventricle study.
        Circulation. 2011; 123: 2542-2551
        • Thiruvenkatarajan V
        • Meyer EJ
        • Nanjappa N
        • Van Wijk RM
        • et al.
        Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: A systematic review.
        Br J Anaesth. 2019; 123: 27-36
        • Handelsman Y
        • Henry RR
        • Bloomgarden ZT
        • et al.
        American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis.
        Endocr Pract. 2016; 2 (753e62)
        • Abu-Omar Y
        • Kocher GJ
        • Bosco P
        • et al.
        European association for cardiothoracic surgery expert consensus statement on the prevention and management of mediastinitis.
        Eur J Cardiothorac Surg. 2017; 51: 10-29
        • Lazar HL
        • Salm TV
        • Engelman R
        • et al.
        Prevention and management of sternal wound infections.
        J Thorac Cardiovasc Surg. 2016; 152: 962-972